Distinguished in Virilizing Ovarian Tumor

Dr. Richard T. Penson

Massachusetts General Physicians Organization Inc
Boston, MA
Distinguished
in Virilizing Ovarian Tumor
Specialties:Oncology | Hematology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Richard Penson is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Penson and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Gastrostomy. Dr. Penson is currently accepting new patients.

His clinical research consists of co-authoring 117 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Massachusetts General Hospital
Cooley Dickinson Hospital Inc,the
Languages Spoken
English
French
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Tufts
  •  Ambetter

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114
617-724-0287

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Nivolumab, Rucaparib
Study Phase: Phase 2
A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer, Avelumab / Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer, and Avelumab / Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer, Avelumab / Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer, and Avelumab / Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 05, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Talazoparib, Axitinib
Study Phase: Phase 2
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: Entinostat, Avelumab
Study Phase: Phase 1/Phase 2
A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 03, 2024
Intervention Type: Drug
Study Drug: AZD1775
Study Phase: Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
View 4 Less Clinical Trials

117 Total Publications

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 12, 2024
Similar Doctors
Expertise in
10
conditions
Dr. Carolyn N. Krasner
Hematology | Oncology
Expertise in
10
conditions
Dr. Carolyn N. Krasner
Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.7 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carolyn Krasner is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Krasner and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Salpingo-Oophorectomy. Dr. Krasner is currently accepting new patients.

Expertise in
13
conditions
Dr. Susana M. Campos
Oncology | Hematology | Hematology Oncology
Expertise in
13
conditions
Dr. Susana M. Campos
Oncology | Hematology | Hematology Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.7 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Susana Campos is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Campos and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, and Ovarian Carcinosarcoma. Dr. Campos is currently accepting new patients.

Expertise in
11
conditions
Dr. Ursula A. Matulonis
Oncology
Expertise in
11
conditions
Dr. Ursula A. Matulonis
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.7 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ursula Matulonis is an Oncologist in Boston, Massachusetts. Dr. Matulonis and is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Tubal Ligation. Dr. Matulonis is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile